By101921

PARP7 inhibitor · Chengdu Baiyu Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for By101921, covering 2024-05-30 to 2024-05-30. Get the full timeline:

Most recent: Clinical Trial Update: A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors [Phase 1]